116 Publications (Page 3 of 5)
2011
The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells
Zhang, ShuhongZhang, ShuhongSuvannasankha, AttayaSuvannasankha, AttayaCrean, Colin DCrean, Colin DWhite, Valerie LWhite, Valerie LChen, Ching ShihChen, Ching‐ShihFarag, Sherif S and Farag, Sherif S
International Journal of Cancer, vol. 129, (no. 1), pp. 204-213, 2011. | Journal Article
 
The potential role of Aurora kinase inhibitors in haematological malignancies.
Farag, Sherif S
British journal of haematology, vol. 155, (no. 5), pp. 561-79, 2011/Dec. | Journal Article
2010
Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
Nelson, Robert PYu, MenggangSchwartz, JenniferRobertson, Michael JHromas, Robert AFausel, C AVance, Gail HDlouhy, Stephen RBaute, J ACox, E AWood, L LSrivastava, ShivaniRobertson, KentHaut, P RFarag, Sherif SAbonour, RafatCornetta, Kenneth G and Cripe, Larry D
Bone marrow transplantation, vol. 45, (no. 8), pp. 1300-8, 2010/Aug. | Journal Article
 
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma
Wang, XiaojingWang, XiaojingWang, XiaojingWang, XiaojingSinn, AnthonySinn, AnthonySinn, AnthonySinn, Anthony LPollok, KarenPollok, KarenPollok, KarenPollok, KarenSandusky, GeorgeSandusky, GeorgeSandusky, GeorgeSandusky, GeorgeZhang, ShuhongZhang, ShuhongZhang, ShuhongZhang, ShuhongChen, LiChen, LiChen, LiChen, LiLiang, JingLiang, JingLiang, JingLiang, JingCrean, Colin DCrean, ColinCrean, ColinCrean, ColinSuvannasankha, AttayaSuvannasankha, AttayaSuvannasankha, AttayaSuvannasankha, AttayaAbonour, RafatAbonour, RafatAbonour, RafatAbonour, RafatSidor, CarolynSidor, CarolynSidor, CarolynSidor, CarolynBray, MarkBray, MarkBray, Mark RBray, MarkFarag, SherifFarag, SherifFarag, Sherif and Farag, Sherif S
British Journal of Haematology, vol. 150, (no. 3), pp. 313-325, 2010. | Journal Article
 
Quantification of non-specific binding of magnetic micro- and nanoparticles using cell tracking velocimetry: Implication for magnetic cell separation and detection
Chalmers, Jeffrey JohnXiong, Y.Jin, X.Shao, M.Tong, X.Farag, S. and Zborowski, Maciej
Biotechnology and Bioengineering, vol. 105, (no. 6), Apr 15, 2010. | Journal Article
2009
Natural killer cell activity and killer immunoglobulin-like receptors in hematopoietic stem cell transplantation.
Ruggeri, LoredanaRuggeri, LoredanaZhang, ShuhongZhang, ShuhongFarag, Sherif S and Farag, Sherif S
Cancer treatment and research, vol. 144, pp. 47-69, 2009. | Journal Article
 
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
Farag, Sherif SFarag, SherifZhang, ShuhongZhang, ShuhongJansak, Buffy SJansak, BuffyWang, XiaojingWang, XiaojingKraut, Eric HKraut, EricChan, Kenneth KChan, KennethDancey, JanetDancey, Janet EGrever, Michael R and Grever, Michael
Leukemia Research, vol. 33, (no. 11), pp. 1475-1480, 2009. | Journal Article
 
Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma
Hofmeister, Craig CBenson, DonEfebera, Yvonne AFarag, Sherif and Grever, Michael R
Blood, vol. 114, (no. 22), pp. 2884, 2009-11-20. | Journal Article
2008
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
Hamadani, Sayed MHofmeister, Craig CJansak, BuffyPhillips, GaryElder, PatrickBlum, WilliamPenza, Sam LLin, Thomas SKlisovic, RebeccaMarcucci, GuidoFarag, Sherif S and Devine, Steven M
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, vol. 14, (no. 7), pp. 783-9, 2008/Jul. | Journal Article
 
Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide
Suvannasankha, AttayaSuvannasankha, AttayaSuvannasankha, AttayaCrean, ColinCrean, ColinCrean, Colin DShanmugam, RajasubramaniamShanmugam, RajasubramaniamShanmugam, RajasubramaniamFarag, SherifFarag, Sherif SFarag, SherifAbonour, RafatAbonour, RafatAbonour, RafatBoswell, H.Boswell, HScottBoswell, H.Nakshatri, HarikrishnaNakshatri, Harikrishna and Nakshatri, Harikrishna
Clinical Cancer Research, vol. 14, (no. 6), pp. 1814-1822, 2008. | Journal Article
 
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma
Hofmeister, Craig CJansak, B.Denlinger, N.Kraut, Eric HBenson, Don M and Farag, Sherif S
Leukemia Research, vol. 32, (no. 8), pp. 1295-1298, 2008. | Journal Article
 
Synergistic Activity of Bendamustine in Combination with Doxorubicin and Bortezomib in Multiple Myeloma Cells
Zhang, ShuhongZhang, ShuhongZhang, ShuhongZhang, ShuhongWang, XiaojingWang, XiaojingWang, XiaojingWang, XiaojingChen, LiChen, LiChen, LiChen, LiLiang, JingLiang, JingLiang, JingLiang, JingSuvannasankha, AttayaSuvannasankha, AttayaSuvannasankha, AttayaSuvannasankha, AttayaAbonour, RafatAbonour, RafatAbonour, RafatAbonour, RafatFarag, Sherif SFarag, Sherif SFarag, Sherif S and Farag, Sherif S
Blood, vol. 112, (no. 11), pp. 5171, 2008-11-16. | Journal Article
 
The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo, and Shows Synergistic Activity in Combination with Lenalidomide
Wang, XiaojingWang, XiaojingWang, XiaojingWang, XiaojingWang, XiaojingWang, XiaojingSinn, Anthony LSinn, Anthony LSinn, Anthony LSinn, Anthony LSinn, Anthony LSinn, Anthony LSuvannasankha, AttayaSuvannasankha, AttayaSuvannasankha, AttayaSuvannasankha, AttayaSuvannasankha, AttayaSuvannasankha, AttayaCrean, Colin DCrean, Colin DCrean, Colin DCrean, Colin DCrean, Colin DCrean, Colin DChen, LiChen, LiChen, LiChen, LiChen, LiChen, LiZhang, ShuhongZhang, ShuhongZhang, ShuhongZhang, ShuhongZhang, ShuhongZhang, ShuhongLiang, JingLiang, JingLiang, JingLiang, JingLiang, JingLiang, JingZhang, GenglinZhang, GenglinZhang, GenglinZhang, GenglinZhang, GenglinZhang, GenglinPollok, Karen EPollok, Karen EPollok, Karen EPollok, Karen EPollok, Karen EPollok, Karen EAbonour, RafatAbonour, RafatAbonour, RafatAbonour, RafatAbonour, RafatAbonour, RafatSidor, CarolynSidor, CarolynSidor, CarolynSidor, CarolynSidor, CarolynSidor, CarolynBray, Mark RBray, Mark RBray, Mark RBray, Mark RBray, Mark RBray, Mark RFarag, Sherif SFarag, Sherif SFarag, Sherif SFarag, Sherif SFarag, Sherif S and Farag, Sherif S
Blood, vol. 112, (no. 11), pp. 3660, 2008-11-16. | Journal Article
2007
A novel high throughput immunomagnetic cell sorting system for potential clinical scale depletion of T cells for allogeneic stem cell transplantation.
Tong, XiaodongXiong, YingZborowski, MaciejFarag, Sherif S and Chalmers, Jeffrey John
Experimental hematology, vol. 35, (no. 10), pp. 1613-22, 2007/Oct. | Journal Article
 
Blood progenitor cell separation from clinical leukapheresis product by magnetic nanoparticle binding and magnetophoresis
Jing, YingJing, YingMoore, Lee RMoore, Lee RWilliams, P. SWilliams, P. StephenChalmers, Jeffrey JohnChalmers, Jeffrey JFarag, Sherif SFarag, Sherif SBolwell, BrianBolwell, BrianZborowski, Maciej and Zborowski, Maciej
Biotechnology and Bioengineering, vol. 96, (no. 6), pp. 1154, 15 April 2007. | Journal Article
 
High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
Benson, Don MElder, Patrick JLin, Thomas SBlum, WilliamPenza, Sam LAvalos, Belinda RCopelan, Edward A and Farag, Sherif S
Leukemia Research, vol. 31, (no. 8), pp. 1069-1075, 2007. | Journal Article
 
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.
Miller, Jeffery SCooley, Sarah AParham, PeterFarag, Sherif SVerneris, Michael RMcQueen, Karina LGuethlein, Lisbeth ATrachtenberg, Elizabeth AHaagenson, MichaelHorowitz, Mary MKlein, John P and Weisdorf, Dan
Blood, vol. 109, (no. 11), pp. 5058-61, 2007/Jun/1. | Journal Article
 
Multiple myeloma. Clinical practice guidelines in oncology
Anderson, Kenneth CAnderson, Kenneth CAnderson, Kenneth CAlsina, MelissaAlsina, MelissaAlsina, MelissaBensinger, WilliamBensinger, WilliamBensinger, WilliamBiermann, J SBiermann, J SybilBiermann, J SybilChanan-Khan, AsherChanan-Khan, AsherChanan-Khan, AsherComenzo, Raymond LComenzo, Raymond LComenzo, Raymond LDe Castro, Carlos MDe Castro, Carlos MDe Castro, Carlos MDjulbegovic, BenjaminDjulbegovic, BenjaminDjulbegovic, BenjaminFarag, SherifFarag, SherifFarag, SherifHuff, Carol AHuff, Carol AnnHuff, Carol AnnMeredith, RubyMeredith, RubyMeredith, RubySchriber, JeffreySchriber, JeffreySchriber, JeffreyShrieve, DennisShrieve, DennisShrieve, DennisSinghal, SeemaSinghal, SeemaSinghal, SeemaSmith, Mitchell RSmith, Mitchell RSmith, Mitchell RStockerl-Goldstein, KeithStockerl Goldstein, Keith EStockerl-Goldstein, KeithVose, Julie MVose, Julie MVose, Julie MWeber, DonnaWeber, DonnaWeber, DonnaYahalom, JoachimYahalom, JoachimYahalom, JoachimYunus, FurhanYunus, Furhan and Yunus, Furhan
Journal of the National Comprehensive Cancer Network : JNCCN, vol. 5, (no. 2), pp. 118, 2007-Feb. | Journal Article
 
Negative selection of hematopoietic progenitor cells by continuous magnetophoresis
Jing, YingJing, YingMoore, Lee RMoore, LeeSchneider, ThomasSchneider, ThomasWilliams, P. SWilliams, P.Chalmers, Jeffrey JohnChalmers, JeffreyFarag, Sherif SFarag, SherifBolwell, BrianBolwell, BrianZborowski, Maciej and Zborowski, Maciej
Experimental Hematology, vol. 35, (no. 4), pp. 672, 2007. | Journal Article
 
OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
Zhang, ShuhongZhang, ShuhongZhang, ShuhongSuvannasankha, AttayaSuvannasankha, AttayaSuvannasankha, AttayaCrean, ColinCrean, Colin DCrean, ColinWhite, ValerieWhite, Valerie LWhite, ValerieJohnson, AmyJohnson, AmyJohnson, AmyChen, Ching ShihChen, Ching-ShihChen, Ching-ShihFarag, SherifFarag, Sherif and Farag, Sherif S
Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 13, (no. 16), pp. 4750-8, 2007/Aug/15. | Journal Article
 
Unlike Inactivating PTEN Mutations, Pharmacological Inhibition of PTEN Does Not Increase the Sensitivity of Multiple Myeloma Cells to Inhibition of the PI3K/Akt/mTOR Pathway
Wang, XiaojingWang, XiaojingZhang, ShuhongZhang, ShuhongPeng, XiaodongPeng, XiaodongGarlich, JoeGarlich, JoeChen, LiChen, LiLiang, JingLiang, JingFarag, Sherif Shafik and Farag, Sherif Shafik
Blood, vol. 110, (no. 11), pp. 4785, 2007-11-16. | Journal Article
2006
Comparison of two immunomagnetic separation technologies to deplete T cells from human blood samples
Lara, OscarLara, OscarTong, XiaodongTong, XiaodongZborowski, MaciejZborowski, MaciejFarag, Sherif SFarag, Sherif SChalmers, Jeffrey John and Chalmers, Jeffrey J
Biotechnology and Bioengineering, vol. 94, (no. 1), pp. 80, 5 May 2006. | Journal Article
 
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
Blum, WilliamBolwell, Brian JPhillips, GaryFarag, Sherif SLin, Thomas SAvalos, Belinda RPenza, Sam LMarcucci, GuidoByrd, John CKalaycio, Matt ESobecks, Ronald MPohlman, BradBrown, StaceyElder, Patrick J and Copelan, Edward A
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, vol. 12, (no. 1), pp. 61-7, 2006/Jan. | Journal Article
 
Human natural killer cell development and biology.
Farag, Sherif S and Caligiuri, Michael A
Blood reviews, vol. 20, (no. 3), pp. 123-37, 2006/May. | Journal Article
 
Immunologic approaches to acute leukemia in the elderly.
Farag, Sherif S and Caligiuri, Michael A
Seminars in hematology, vol. 43, (no. 2), pp. 118-25, 2006/Apr. | Journal Article